Barely Significant

Excerpts

514,629 sentences

highly significantP <0.0010.0× alphaqualifiedgold
The prevalence rates in Western European (10.9%) and ethnic minority women (14.6%) with the WHO criteria were not significantly different ( P =0.14), but with the modified IADPSG criteria, the difference was highly significant (24 and 36.8% respectively, P <0.001; Fig. 1 , Table 2 ).
highly significantp < 0.0010.0× alphaqualifiedgold
However, when patients from each group were sub-divided into those presenting with VAP or not during the course of their hospitalization, there were significant differences within the placebo and probiotic groups: placebo-treated patients who did not experience VAP [no-VAP group] were found to have a statistically highly significant increase in neutrophils [ p < 0.001] between days 0 and 7; and the same was observed in the probiotics/no-VAP group.
highly significantp < 0.0010.0× alphaqualifiedgold
In addition, a comparison of all pairwise F ST values among the 52 populations showed a highly significant correlation among the F ST values calculated based on the 41-AIM panel and the 31-AIM panel (Mantel test, r = 0.987, p < 0.001), further indicating no significant loss of power to discern global ancestry in the smaller panel.
a positive trendp < .0010.0× alphagold
In contrast, NB+ cells displayed a positive trend ( p < .001), suggesting a slightly enhanced cAMP production in response to NA stimulation in the cell processes (Figure 6d , right). 4 DISCUSSION Previous studies on cultured astrocytes revealed that Ca 2+ signaling is phasic and fast, whereas cAMP signaling exhibits tonic and slower dynamics (Horvat et al., 2016 ), which was subsequently confirmed in an in vivo system (Oe et al., 2020 ), validating the use of cultured cells to study basic cell processes.
highly significantp = 0.0010.0× alphaqualifiedgold
The receipt of 3 doses of the BNT 162b2 mRNA vaccine was associated with a highly significant 96% reduction in COVID-19 infection (aHR 0.04, 95% CI 0.01-0.27, p = 0.001), a 91% reduction in symptomatic COVID-19 (aHR 0.01-0.71, p = 0.02), a 100% reduction in moderate, severe or critical COVID-19 (aHR 0.00, 95% CI 0.00-0.04, p < 0.001), and a 100% reduction in severe or critical COVID-19 (aHR 0.0, 95% CI 0.00-0.02, p < 0.001) compared to participants who received 2 doses ( Table 4 ).